Age and Gleason's Score in Prostate Cancer among Southern Nigerians: Is there Any Correlation?
Journal of Cancer and Tumor International,
Page 8-15
DOI:
10.9734/jcti/2022/v12i230171
Abstract
Background: Prostate cancer (PCa) incidence and mortality are associated with age and African descent. African men are more likely to have aggressive disease, present late with complications and die from prostate cancer. Age is also an independent factor for consideration in the management of patients with PCa. The Gleason score is used both for risk classification, treatment stratification and prognostic purposes.
Objective: To determine the presence of a correlation between age and Gleason score in patients with histologically confirmed prostate cancer.
Materials and methods: This retrospective study was carried out on patients with histologically confirmed prostate cancer from August 2012 to July 2021. Their case records were retrieved, and the patient's age and Gleason grade were collated. Data collected were then analyzed using SPSS version 20. The data were collated using Microsoft excel 2016.
Results: There were 352 patients with histologically confirmed prostate cancer with a mean age of 68.88years±9.75, ranging from 48years to 117years. The modal age range was the 60-69year group. The commonest PCa grade is Gleason 8/Grade group 4 {27.8% (98)}, followed by Gleason 9/Grade group 5 {19.9% (70)} as shown in Fig. 2. The Gleason score was associated with age as indicated in Table 2 (p=0.001). However, Pearson's correlation coefficient did not establish a statistically significant relationship (r=0.045; p=0.401). The high-risk Gleason's 8-10, Grade group 4 and 5, was the most frequent among all the age groups. The low Gleason score cancers were commonest in the 40-49year age group.
Conclusion: There was an association between age and Gleason's score, even though it was not statistically significant. Gleason 8-10 /Grade groups 4 and 5 PCa was associated with older patients. It was also commonest among patients 80years and above.
Keywords:
- Age
- correlation
- Gleason score
- ISUP
- prostate cancer
How to Cite
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Bosland MC, Nettey OS, Phillips AA, Anunobi CC, Akinloye O, Ekanem IO et al. Prevalence of prostate cancer at autopsy in Nigeria—A preliminary report. The Prostate. 2021;81(9):553-559.
Oluwole OP, Rafindadi AH, Shehu MS, Samaila MO. A ten-year study of prostate cancer specimens at Ahmadu Bello University Teaching Hospital (ABUTH), Zaria, Nigeria. African journal of urology. 2015;21(1):15-18.
Raphael JE, Abhulimen V. Retrospective Analysis of Complications from Prostate Cancer among Nigerians. Saudi J Med. 2022;7(2):99-104.
Chen N, Zhou Q. The evolving Gleason grading system. Chinese Journal of Cancer Research. 2016; 28(1):58.
Bauckneht M, Rebuzzi SE, Signori A, Donegani MI, Murianni V, Miceli A, Borea R, Raffa S, Damassi A, Ponzano M, Catalano F. The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with radium-223: a proof-of-concept study. Cancers. 2020;12(11): 3213.
Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D'Andrea D, Korn SM, Pones M, Kramer G, Karakiewicz P, Enikeev DV, Glybochko PV, Briganti A. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. InUrologic Oncology: Seminars and Original Investigations 2020 (Vol. 38, No. 6, pp. 600-e9). Elsevier.
Kreuz M, Otto DJ, Fuessel S, Blumert C, Bertram C, Bartsch S, Loeffler D, Puppel SH, Rade M, Buschmann T, Christ S. ProstaTrend—a multivariable prognostic RNA expression score for aggressive prostate cancer. European Urology. 2020; 78(3):452-9.
Basiri A, Eshrati B, Zarehoroki A, Golshan S, Shakhssalim N, Khoshdel A, Kashi AH. Incidence, Gleason score and ethnicity pattern of prostate cancer in the multi-ethnicity country of Iran during 2008-2010. Urology Journal. 2020; 17(6):602-6.
Huynh‐Le MP, Myklebust TÅ, Feng CH, Karunamuni R, Johannesen TB, Dale AM, Andreassen OA, Seibert TM. Age dependence of modern clinical risk groups for localized prostate cancer—A population‐based study. Cancer. 2020; 126(8):1691-9.
Shah N, Ioffe V. Frequency of Gleason score 7 to 10 in 5100 elderly prostate cancer patients. Reviews in Urology. 2016; 18(4):181.
Fapohunda A, Fakolade A, Omiye J, Afolaranmi O, Arowojolu O, Oyebamiji T, Nwogu C, Olawaiye A, Mutiu J. Cancer presentation patterns in Lagos, Nigeria: Experience from a private cancer center. Journal of public health in Africa. 2020;11(2).
Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, Stattin P, Van Poppel H, La Vecchia C. Epidemiology and prevention of prostate cancer. European urology oncology. 2021.
Oladoyinbo CA, Akinbule OO, Sobo AA, Bolajoko OO, Bassey IE, Prostate Cancer Transatlantic Consortium Members. Behavioural risk factors associated with prostate cancer: the prostate cancer transatlantic consortium (CaPTC) cohort study.
Eke NS, Sapira MK. Prostate cancer in Port Harcourt, Nigeria: features and outcome. Nigerian Journal of Surgical Research. 2002;4(1):34-44.
Ekeke ON, Amusan OE, Eke N. Management of prostate cancer in Port Harcourt, Nigeria: Changing patterns. Journal of the West African College of Surgeons. 2012; 2(3):58.
Abdulkadir A, Alhaji SA, Sanusi HM. Pattern of urological cancers in Kano: North-western Nigeria. Sub-Saharan African Journal of Medicine. 2016;3(4):182.
Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU international. 2005; 95(1):59-63.
Gupta S, Gupta A, Saini AK, Majumder K, Sinha K, Chahal A. Prostate Cancer: How Young is too Young?. Curr Urol. 2017;9(4): 212-215. doi:10.1159/000447143
Guo W, Zhang J, Zhou Y, Zhou C, Yang Y, Cong Z, Dong J, Yang D, Dai B, Wang MW. GPR160 is a potential biomarker associated with prostate cancer. Signal transduction and targeted therapy. 2021; 6(1):1-3.
Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, DiPaola RS, Lu-Yao GL. Contemporary risk profile of prostate cancer in the United States. JNCI: Journal of the National Cancer Institute. 2009; 101(18):1280-3.
Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone‐ releasing hormone agonists for prostate cancer. BJU international. 2000; 86(4):449-52.
Abu-Hamar Ael H, Gameel TA. Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment. J Egypt Natl Canc Inst. 2009;21(3):229-236.
Wenzel M, Würnschimmel C, Chierigo F, et al. Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy [published online ahead of print. Eur Urol Focus. 2021;S2405-4569(21): 00117-6.
Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2018;199(3):683-690.
25Huynh‐Le MP, Myklebust TÅ, Feng CH, Karunamuni R, Johannesen TB, Dale AM, Andreassen OA, Seibert TM. Age dependence of modern clinical risk groups for localized prostate cancer—A population‐based study. Cancer. 2020;126(8):1691-9.
26Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezolosky MD, Viswanathan VB, Choueiri TK, Sweeney CJ, Trinh QD, Nguyen PL. Association between older age and increasing Gleason score. Clinical genitourinary cancer. 2015;13(6): 525-30.
-
Abstract View: 120 times
PDF Download: 35 times
